Natco Pharma's Generic Semaglutide to Hit Indian Market in March

Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus and is used as an adjunct to diet and exercise. With this approval, NATCO will be able to manufacture and commercialize the generic version of Semaglutide Injection in the domestic market beginning March 2026.

Headquartered in Hyderabad, NATCO Pharma Limited develops, manufactures, and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients, and crop protection products. The company describes itself as an R&D-oriented and science-driven organization and is a leading oncology player in the targeted therapies segment of the domestic market, with a focus on limited competition molecules in the United States.

NATCO operates nine manufacturing sites and two R&D facilities in India. Its manufacturing facilities are approved by several leading regulatory authorities, including the U.S. FDA, Brazil's ANVISA, Health Canada, and WHO, catering to more than 50 global markets, according to a press release issued by the company.